Where can I find the European Commission (EC) approval for VAZKEPA® (icosopent ethyl) to reduce the risk of cardiovascular events in patients at high cardiovascular risk?

On March 26, 2021, the EC granted marketing authorization for Amarin's drug VAZKEPA® (icosapent ethyl) and on March 30, 2021 published its decision in the Register of Medicinal Products, which can be found here.

For more information, please refer to the Amarin press release published March 30, 2021 titled, Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk, here.

In accordance with European regulatory guidelines and strategy regarding optimizing market access, Amarin's press release regarding this marketing authorization addresses the authorization only. Amarin's plans for pursuing market access for VAZKEPA, and discussion of the large unmet medical need, can be found here.

Dated: March 30, 2021

Note: VAZKEPA is a registered trademark of Amarin Pharmaceuticals Ireland Limited in Europe and other countries and regions and is pending registration in the United States.